Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexobrutideg - Nurix

Next Previous
Drug Profile

Bexobrutideg - Nurix

Alternative Names: BTK-IN-24; NX-5948

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nurix
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Phase I Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Preclinical Autoimmune disorders; Haemophagocytic lymphohistiocytosis
  • Discontinued Graft-versus-host disease; Rhabdomyosarcoma; Rheumatoid arthritis

Most Recent Events

  • 29 Jan 2026 Nurix plans a pivotal phase III DAYBreak CLL-306 trial for Chronic lymphocytic leukaemia (Second line therapy or greater, Monotherapy) (PO), in the first half of 2026
  • 12 Jan 2026 Nurix plans to submit an IND application for a new tablet formulation of bexobrutideg for Autoimmune and inflammatory conditions, in 2026
  • 08 Dec 2025 Updated efficacy and adverse events data from a phase Ia/Ib trial in Waldenstrom’s Macroglobulinemia released by Nurix Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top